Multivalent recombinant OspA vaccine (Baxter Healthcare)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMultivalent recombinant OspA vaccine (Baxter Healthcare)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLyme Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustriaGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaxter International Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaxalta Incorporated
Active IndicationsN/A
Inactive IndicationsLyme Disease

Other Information

ATC CodeN/A
Related LinksN/A